Effects of High Dose Bolus Cholecalciferol on Free Vitamin D Metabolites, Bone Turnover Markers and Physical Function.

Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI Publishing

Cholecalciferol*/administration & dosage ; Bone Remodeling*/drug effects ; Biomarkers*/blood ; Biomarkers*/urine ; Vitamin D*/analogs & derivatives ; Vitamin D*/blood ; Vitamin D*/administration & dosage ; Dietary Supplements* ; Vitamin D Deficiency*/drug therapy ; Vitamin D Deficiency*/blood; Humans ; Female ; Middle Aged ; Double-Blind Method ; Aged ; Postmenopause ; Calcium/blood ; Parathyroid Hormone/blood ; Fibroblast Growth Factor-23 ; Dose-Response Relationship, Drug

High dose bolus cholecalciferol supplementation has been associated with falls and fracture, and this does not appear to be due to hypercalcaemia. The primary aim of this study was to determine the change in free vitamin D and metabolites after high dose bolus supplementation. This was a single centre, double-blinded, randomised, controlled trial of three different oral bolus doses of vitamin D 3 (50,000 IU, 150,000 IU, and 500,000 IU) in otherwise healthy, vitamin D deficient (total 25-hydroxylated vitamin 25(OH)D < 30 nmol/L) postmenopausal women. Thirty-three women were randomized to one of the three treatment groups. Twenty-seven vitamin D sufficient (25(OH)D > 50 nmol/L) postmenopausal women were recruited as a concurrent control group. Participants attended five study visits over three months. We measured total 25(OH)D 3 and free 25(OH)D, total and free 1,25(OH) 2 D, parathyroid hormone, fibroblast-growth factor-23, serum calcium, ionised calcium, urinary calcium excretion, and bone turnover markers (procollagen I N-propeptide (PINP), serum C-telopeptides of type I collagen (CTX-I) and Osteocalcin (OC)). We assessed muscle strength and function with grip strength and a short physical performance battery. Postural blood pressure and aldosterone:renin ratio (ARR) was also measured. Total 25(OH)D 3 and free 25(OH)D increased in response to dose, and there were proportionate increases in total and free metabolites. Treatment did not affect serum calcium, postural blood pressure, ARR, or physical function. Bone turnover markers increased transiently one week after administration of 500,000 IU. High dose bolus cholecalciferol supplementation does not cause disproportionate increases in free vitamin D or metabolites. We did not identify any effect on blood pressure regulation or physical function that would explain increased falls after high dose treatment. A transient increase in bone turnover markers one week after a 500,000 IU bolus suggests that very high doses can have acute effects on bone metabolism, but the clinical significance of this transient increase is uncertain.

J Clin Invest. 2002 Jul;110(2):229-38. (PMID: 12122115)
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3278-3288. (PMID: 29955795)
Nat Rev Cardiol. 2009 Oct;6(10):621-30. (PMID: 19687790)
J Endocrinol Invest. 2013 Dec;36(11):1051-4. (PMID: 23888368)
J Bone Miner Res. 2007 Dec;22 Suppl 2:V64-8. (PMID: 18290725)
Clin Endocrinol (Oxf). 2010 Apr;72(4):455-61. (PMID: 19486025)
Am J Clin Nutr. 2008 Aug;88(2):491S-499S. (PMID: 18689389)
JAMA Intern Med. 2016 Feb;176(2):175-83. (PMID: 26747333)
N Engl J Med. 2012 Jul 5;367(1):77-8. (PMID: 22762324)
Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):531-41. (PMID: 21872796)
Hypertension. 2007 May;49(5):1063-9. (PMID: 17372031)
J Clin Densitom. 2017 Jul - Sep;20(3):346-352. (PMID: 28716498)
J Clin Endocrinol Metab. 2010 Oct;95(10):4771-7. (PMID: 20660032)
Hypertension. 2008 Dec;52(6):1106-12. (PMID: 18936343)
Am J Physiol Renal Physiol. 2007 Nov;293(5):F1577-83. (PMID: 17699549)
J Clin Endocrinol Metab. 2013 Jul;98(7):2709-15. (PMID: 23766519)
J Nutr. 2006 Feb;136(2):440-5. (PMID: 16424125)
Calcif Tissue Int. 2012 Dec;91(6):365-9. (PMID: 23052222)
J Bone Miner Metab. 2008;26(6):603-8. (PMID: 18979160)
J Clin Endocrinol Metab. 2016 May;101(5):2226-34. (PMID: 27007693)
Kidney Int. 2012 Jul;82(1):84-9. (PMID: 22398410)
Bone Miner. 1990 Dec;11(3):267-72. (PMID: 2085680)
Drugs Aging. 2009;26(10):861-9. (PMID: 19761279)
Front Cardiovasc Med. 2018 Jul 12;5:87. (PMID: 30050908)
Burns. 2015 Aug;41(5):1028-34. (PMID: 25529268)
Hypertension. 1997 Nov;30(5):1289-94. (PMID: 9369290)
Curr Med Res Opin. 2007 Jun;23(6):1227-37. (PMID: 17559732)
Calcif Tissue Int. 2020 Jan;106(1):47-57. (PMID: 31312865)
Ann Intern Med. 1995 Apr 1;122(7):511-3. (PMID: 7872586)
Am J Hypertens. 1995 Sep;8(9):894-901. (PMID: 8541004)
Front Endocrinol (Lausanne). 2019 May 28;10:317. (PMID: 31191450)
JAMA. 2010 May 12;303(18):1861-2. (PMID: 20460627)
Contemp Clin Trials. 2006 Jun;27(3):215-26. (PMID: 16581307)
Nutrients. 2010 Sep;2(9):975-984. (PMID: 22254066)
Lancet. 2007 Aug 25;370(9588):657-66. (PMID: 17720017)
JBMR Plus. 2021 Nov 15;5(12):e10575. (PMID: 34950830)
Calcif Tissue Int. 2013 Feb;92(2):191-206. (PMID: 23250508)
Rheumatology (Oxford). 2007 Dec;46(12):1852-7. (PMID: 17998225)
Arch Biochem Biophys. 1995 Jun 1;319(2):535-9. (PMID: 7786039)
J Clin Endocrinol Metab. 2008 Aug;93(8):3015-20. (PMID: 18492750)
Maturitas. 2018 May;111:47-52. (PMID: 29673831)
Curr Rheumatol Rep. 2011 Jun;13(3):257-64. (PMID: 21369796)
Am J Public Health. 1995 May;85(5):656-9. (PMID: 7733425)
Endocrinology. 2011 Feb;152(2):354-63. (PMID: 21190957)
J Bone Miner Res. 2004 Mar;19(3):429-35. (PMID: 15040831)
J Cell Biochem. 2003 Feb 1;88(2):327-31. (PMID: 12520534)
Am J Clin Nutr. 2008 Aug;88(2):582S-586S. (PMID: 18689406)
JAMA. 2010 May 12;303(18):1815-22. (PMID: 20460620)
Rejuvenation Res. 2014 Jun;17(3):276-84. (PMID: 24387140)

235/366 Royal Osteoporosis Society

Keywords: bolus dose vitamin D; bone turnover; falls and fracture; free vitamin D; physical function; vitamin D supplementation; vitamin D toxicity

1C6V77QF41 (Cholecalciferol)
0 (Biomarkers)
1406-16-2 (Vitamin D)
SY7Q814VUP (Calcium)
0 (Parathyroid Hormone)
7Q7P4S7RRE (Fibroblast Growth Factor-23)

Date Created: 20240914 Date Completed: 20240914 Latest Revision: 20240916

20240916

PMC11397043

10.3390/nu16172888

39275206